Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14507335 | 0.98 | KDM4E (0.62) | KDM4EMAPK1HIF1AADRA1ATSHR | |
| SCHEMBL14073945 | 0.93 | KDM4E (0.57) | KDM4EMAPK1HIF1AADRA1ATSHR | |
| SCHEMBL407248 | 0.91 | TSHR (0.61) | KDM4EMAPK1HIF1AADRA1ATSHR | |
| SCHEMBL860790 | 0.84 | KDM4E (0.56) | KDM4EMAPK1HIF1AADRA1ATSHR | |
| SCHEMBL19239219 | 0.83 | TSHR (0.56) | ADRA1ATSHREPHX2LMNAALDH1A1 | |
| SCHEMBL13376980 | 0.83 | RECQL (0.61) | TSHREPHX2LMNAALDH1A1RECQL | |
| SCHEMBL9002644 | 0.83 | EPHX1 (0.64) | ADRA1ATSHREPHX2LMNAALDH1A1 | |
| SCHEMBL6014001 | 0.83 | EPHX1 (0.64) | ADRA1ATSHREPHX2LMNAALDH1A1 | |
| SCHEMBL3407201 | 0.82 | TSHR (0.57) | KDM4EMAPK1HIF1AADRA1ATSHR | |
| SCHEMBL14739904 | 0.82 | KDM4E (1.00) | KDM4EMAPK1HIF1AADRA1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107210-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-04-20 | — | — | US | disclosed |
| US-9371314-B2 | Pyridyl benzothiophenes as kinase inhibitors | ALLERGAN, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160102080-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1979341-A1 | TRISUBSTITUTED AMINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008009348-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-4992472-A | Cancer chemotherapy; nontoxic | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1991-02-12 | — | — | US | disclosed |
| US-4882346-A | TREATING MALIGNANT CELLS WITH 3,3'-(1,6-HEXANDIYL)BIS(5,5-DIMETHYL-2,4-IMIDAZOLINEDIONE) | THE UNITED STATES OF AMERICA AS REPRSENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | KDM4E 309/4885MAPK1 3651/4885HIF1A 3336/4885 |
| US-20160102080-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | PDXK, MAP4K5, MAP4K2 | KDM4E 455/4885MAPK1 118/4885HIF1A 2385/4885 |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | DDT, NIT2, PADI1 | KDM4E 1198/4885MAPK1 3566/4885HIF1A 4660/4885 |
| US-20170107210-A1 | PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS | PDXK, MAP4K5, MAP4K2 | KDM4E 455/4885MAPK1 118/4885HIF1A 2385/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | KDM4E 309/4885MAPK1 3651/4885HIF1A 3336/4885 |
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | KDM4E 418/4885MAPK1 4218/4885HIF1A 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.